Search for: "Regeneron"
Results 21 - 40
of 224
Sorted by Relevance
|
Sort by Date
17 Apr 2024, 8:47 am
The United States announced that it has intervened in a False Claims Act case against New York-based… The post DOJ Files Second Qui Tam Lawsuit Against Regeneron Pharmaceuticals appeared first on TZ Legal - Fraud Fighters. [read post]
1 Jul 2019, 4:15 am
Regeneron Pharmaceuticals Inc. is seeking a patent attorney at the Associate Director level to assist with the development of strategies for expanding Regeneron’s intellectual property protection around key molecules, platforms and other technologies to ensure Regeneron’s long-term competitive advantage. [read post]
27 Mar 2019, 7:15 am
Regeneron Pharmaceuticals Inc. is seeking a patent attorney at the Associate Director level to assist with the development of strategies for expanding Regeneron’s intellectual property protection around key molecules, platforms and other technologies to ensure Regeneron’s long-term competitive advantage.The patent attorney will also provide IP transactional support in partnership with colleagues and clients in R&D, clinical, regulatory, legal, business and… [read post]
28 Dec 2011, 4:46 pm
The second Regeneron product is called Zaltrap, used to treat colorectal cancer. [read post]
31 Jul 2017, 3:30 am
The Federal Circuit issued a decision in Regeneron Pharmaceuticals, Inc. v. [read post]
14 Jul 2008, 4:33 am
Under the agreement, Regeneron would pay the French biotech company $12.45 million for the use the Cellectis patents. [read post]
12 Oct 2017, 8:29 am
” Inequitable Conduct and Regeneron Pharmaceuticals, Inc. v. [read post]
15 May 2023, 1:47 am
On January 26, 2023, Regeneron Pharmaceuticals, Inc., who sought to invalidate Amgen Inc. [read post]
7 Oct 2020, 4:15 am
(Regeneron); Pfizer, Inc. [read post]
19 Feb 2023, 9:16 pm
Noonan -- Sanofi and Regeneron filed their brief at the Supreme Court in Amgen v. [read post]
5 Jan 2019, 4:27 pm
The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Inequitable Conduct After Regeneron: What Litigators, Patent Prosecutors, and Patent Owners Need to Know" on January 10, 2019 from 2:00 to 3:00 pm (ET). [read post]
26 Jan 2016, 4:00 am
The attorney will assume a leadership role in the development, protection, and management of Regeneron’s valuable intellectual property pertaining to biologic processes, manufacturing, formulation, packaging and delivery. [read post]
4 Jul 2013, 8:35 am
In Regeneron at [103] the EWCA remarked, that in the case of a claim to a therapeutical use, the patentee “must show, for example by appropriate experiments, that the product has an effect on a disease process so as to make the claimed therapeutic effect plausible. [read post]
3 Jul 2020, 10:55 pm
Author George Shuklib Licence CC NY-SA 1.0 Source Wikipedia Mouse Jane Lambert Supreme Court (Lords Reed, Hodge, Briggs and Sales and Lady Black) Regeneron Pharmaceuticals Inc v Kymab Ltd [2020] UKSC 27 (24 June 2020) This was an appeal from the Court of Appeal's judgment in Regeneron Pharmaceuticals, Inc v Kymab Ltd and another [2018] EWCA Civ 671 (28 March 2018). [read post]
9 Jul 2020, 1:31 am
Supreme Court against New York biotechnology giant Regeneron in June. [read post]
2 Jul 2020, 6:13 am
However, Kymab claimed that Regeneron’s product claims were not enabled and thus not valid. [read post]
30 Aug 2019, 12:45 pm
The decision was a loss for Amgen, which had claimed that Sanofi and Regeneron's drug Praluent infringed on its patents for the drug Repatha. [read post]
15 Aug 2018, 4:59 pm
Sara MoranFollowing the Court of Appeal’s decision that two of Regeneron’s patents were valid and infringed, it refused to grant Kymab permission to appeal to the Supreme Court, but held that the injunction against Kymab should be stayed, subject to certain conditions, whilst Kymab applied directly to the Supreme Court for permission to appeal. [read post]
14 Dec 2020, 10:31 pm
Jane LambertPatents Court (Mr Justice Birss) Regeneron Pharmaceuticals, Inc. and another v Rinat Neuroscience Corp. [2020] EWHC 3359 (Pat) (7 Dec 2020)Interest rei publicae ut sit finis litium. [read post]
24 Jun 2020, 1:15 pm
(Regeneron Pharmaceuticals Inc v Kymab Ltd. [2020] UKSC 27.) [read post]
